Cartilage is famously bad at healing itself. It has no blood supply, so once it wears down, the standard medical playbook is pain management, physical therapy, and eventually a joint replacement. A new Stanford study suggests there may one day be a fourth option: blocking a single protein and letting the cartilage regrow on its own.
The research, led by Helen Blau and Nidhi Bhutani of Stanford’s Baxter Laboratory for Stem Cell Biology and reported in the journal Science, found that inhibiting an enzyme called 15-PGDH triggered dramatic cartilage regeneration in mice. Before you get excited, the important caveat comes first: this has not been shown to work inside a living human joint yet. Here is what the study actually found, and what it does not prove.
How Cartilage Damage Happens
Cartilage is the smooth, rubbery tissue that caps the ends of your bones inside a joint. In the knee it does two jobs: it lets the joint glide without friction, and it absorbs the shock of every step. The problem is structural. Cartilage has almost no blood supply, so it cannot mount the kind of repair response that heals a cut on your skin or a fractured bone. When it wears down, it mostly stays worn down.
Two things destroy it. The first is injury. A torn ACL or meniscus changes how forces move through the knee, and the altered mechanics grind cartilage away in the years that follow. Studies have found that a large share of people with major knee injuries develop osteoarthritis in that joint within a decade or two. The second is age. Cartilage cells, called chondrocytes, slow down over time and maintain the tissue less effectively, while low-grade inflammation quietly accelerates the wear.
That is why the standard playbook is management, not repair. Physical therapy strengthens the muscles around the joint so they absorb more force. Weight control reduces the load with every step. Resistance training that loads the joints helps the whole system, bone included. All of it protects what is left. None of it grows new cartilage. That missing piece is exactly what the Stanford team went after.
What the Researchers Did
15-PGDH is what scientists call a gerozyme, an enzyme that becomes more abundant as we age and contributes to the gradual decline of tissue function. The same Stanford group had previously shown that blocking 15-PGDH increased muscle mass and endurance in old mice, and linked the protein to the regeneration of bone, nerve, and blood cells.
For the cartilage study, the team compared 15-PGDH levels in knee cartilage from young and old mice, then treated older animals with a small-molecule drug designed to block the enzyme. They also tested the treatment after injury, in younger mice with ACL-tear-type knee damage.
What They Found
The results were striking. Older mice with age-related osteoarthritis regrew significant amounts of cartilage after treatment, and the new tissue was hyaline cartilage, the smooth, durable type found in healthy joints, not the weaker fibrocartilage scar tissue that usually forms.
The treated mice also fared better after knee injuries. Mice given the 15-PGDH inhibitor after ACL-type damage developed substantially less osteoarthritis than untreated animals, and showed improvements in movement and weight bearing.
Perhaps the most surprising finding was how the regeneration happened. It did not come from stem cells. Instead, existing cartilage cells called chondrocytes changed their gene activity and shifted back toward a more youthful state, producing healthy tissue again.
The Human Evidence So Far
The team also tested cartilage taken from people undergoing knee replacement surgery for osteoarthritis. After exposure to the 15-PGDH inhibitor outside the body, the human tissue showed changes in gene activity associated with reduced cartilage breakdown and increased production of articular cartilage.
That is a promising signal, but it is not the same as regrowing cartilage inside a living person. Clinical trials will be needed to determine whether the approach is safe and effective in people, and no such drug is available to patients today.
What It Means and What It Doesn’t
It is worth being precise about where this research sits, because the gap between a mouse result and a medicine is where most hype lives.
What it means: aging biology may be a lever for tissue repair. 15-PGDH is a gerozyme, an enzyme that rises with age and drags tissue function down with it. The Stanford group had already linked blocking it to better muscle, bone, nerve, and blood cell regeneration in old mice. Cartilage is the newest tissue on that list, and the pattern is getting harder to dismiss as a fluke. The most surprising detail is the mechanism. The new cartilage did not come from stem cells. Existing chondrocytes reprogrammed themselves toward a more youthful state. That suggests the repair capacity was there all along, suppressed by an aging signal.
What it doesn’t mean: this is not a treatment, and it is not close to one. The human data comes from cartilage removed during knee replacement surgery and treated in a dish. Tissue in a dish does not have an immune system, a bloodstream, or a joint capsule. A drug that works ex vivo still has to prove it can reach the right cells inside a living knee, at the right dose, without side effects elsewhere in the body. Small-molecule drugs taken systemically go everywhere, and 15-PGDH exists in many tissues. Selectivity will be the hard problem.
It also does not mean your supplement stack is doing any of this. Nothing on the market blocks 15-PGDH. If a product cites this study on its label, that is marketing borrowing the credibility of science it has nothing to do with.
What This Means for You Right Now
Nothing you can buy today blocks 15-PGDH or regrows cartilage. Anyone selling a “cartilage regeneration” supplement based on this study is selling hype, not science.
What you can do today is protect the cartilage you have. If joint health is your concern, start with the basics: the best exercises for bone density do double duty for the joints that sit on top of those bones, and the evidence on collagen supplements for joints is worth an honest look.
The bigger picture is what makes this study interesting beyond knees. 15-PGDH is an aging-related enzyme, and the same research program sits squarely in geroscience, the same field driving the ongoing metformin longevity debate. If aging itself is the target, cartilage may be only the beginning.
What’s Next: The Road to a Real Treatment
The next step is the one that matters and the one that takes the longest: human trials. Before that, the researchers need to answer questions the mouse work cannot. Can an inhibitor be delivered to cartilage inside a living joint at effective concentrations? Does blocking 15-PGDH systemically cause problems in tissues where the enzyme serves a purpose? How long does the regenerated cartilage last, and does it hold up under real mechanical load over years?
Drug development from this point typically takes the better part of a decade, and most candidates fail somewhere along the way. That is not pessimism. It is the base rate, and it is why the researchers themselves frame this as early evidence rather than a breakthrough therapy.
The more interesting question is what the program around 15-PGDH represents. This is geroscience: the idea that aging itself is the shared driver of many diseases, and that targeting aging biology could treat several conditions at once. If that framing holds, cartilage is just the proof of concept. The same logic is being tested against muscle loss, bone fragility, and other failures of old tissue. Related non-drug approaches to tissue stimulation, like PEMF for bone growth and stimulation, show how broad the interest in coaxing old tissue to repair itself has become.
For now, the honest position is watchful interest. Follow the trial announcements, not the supplement ads. The science is real. The product is not here yet.
The Bottom Line
A Stanford team regrew knee cartilage in mice by blocking the aging-related protein 15-PGDH, and human cartilage tissue responded in the lab. It is early evidence, not a treatment. The next step is clinical trials in people. Until then, the most reliable joint protection remains boring and free: move regularly, keep your weight in check, and train the muscles around your joints.
